scholarly journals Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97

Diabetes Care ◽  
2020 ◽  
Vol 43 (9) ◽  
pp. 2324-2324
Author(s):  
Christian Hampp ◽  
Richard S. Swain ◽  
Casie Horgan ◽  
Elizabeth Dee ◽  
Yandong Qiang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Diabetes Care ◽  
Sodium Glucose Cotransporter

scholarly journals Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium–Glucose Cotransporter 2 Inhibitor

2020 ◽  
pp. ds200038
Author(s):  
Rhea Teng ◽  
Martin Kurian ◽  
Kelly L. Close ◽  
John B. Buse ◽  
Anne L. Peters ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Sodium Glucose Cotransporter

scholarly journals A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Contrasting the Safety Profile between Sodium-Glucose Cotransporter-2 Inhibitors and Placebo in Type 1 Diabetes Mellitus Patients

2019 ◽  
Vol 25 (3-4) ◽  
pp. 62-73 ◽  
Author(s):  
Sumanta Saha ◽  
Sujata Saha
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Diabetic Ketoacidosis ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Genital Infection ◽  
Adult Type ◽  
Sodium Glucose Cotransporter

<b><i>Background:</i></b> This study aims to contrast the side effects of treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and placebo in insulin-treated adult type 1 diabetes mellitus (T1DM) patients. <b><i>Methods:</i></b> Double-blinded randomized controlled trials that compare the above outcome were searched in electronic databases. Next, the risk of bias in eligible studies was assessed, and comparable outcomes were compared by a random-effects meta-analysis. <b><i>Results:</i></b> Seven eligible papers comprising about 3,900 participants were studied. All trials suffered from an unclear risk of detection bias and performance bias. In comparison with the placebo group, the risk of genital infection (RR = 3.22, <i>p</i> &#x3c; 0.001, 95% CI 2.31–4.49, <i>I</i><sup>2</sup> = 0%) and diabetic ketoacidosis (RR = 2.66, <i>p</i> = 0.002, 95% CI 1.45–4.89, <i>I</i><sup>2</sup> = 0%) was higher in the SGLT2i-treated group. <b><i>Conclusion:</i></b> SGLT2i treatment increased the risk of genital infection and diabetic ketoacidosis in adult insulin-treated T1DM patients.

scholarly journals International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Diabetes Care ◽  
2019 ◽  
Vol 42 (6) ◽  
pp. 1147-1154 ◽  
Author(s):  
Thomas Danne ◽  
Satish Garg ◽  
Anne L. Peters ◽  
John B. Buse ◽  
Chantal Mathieu ◽  
...  
Keyword(s):  
Risk Management ◽  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
International Consensus ◽  
Sodium Glucose Cotransporter

scholarly journals Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes

2018 ◽  
Vol 18 (3) ◽  
pp. 117-121 ◽  
Author(s):  
Umesh Dashora ◽  
Dipesh Patel ◽  
Rob Gregory ◽  
Dinesh Nagi
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Vascular Disease ◽  
Diabetic Ketoacidosis ◽  
Insulin Treatment ◽  
Position Statement ◽  
Treatment Monitoring ◽  
Peripheral Vascular ◽  
Sodium Glucose Cotransporter

SGLT-2 inhibitors are currently neither licensed nor recommended in people with type 1 diabetes. The management of type 1 diabetes consists essentially of insulin treatment, monitoring and education. SGLT-2 inhibitors can be a useful adjunct to insulin treatment in improving glycaemic control. They may also potentially be helpful in reducing cardiovascular and renal complications in people with type 1 diabetes. However, further studies will be needed to establish this. SGLT-2 inhibitors can cause diabetic ketoacidosis and certain circumstances appear to increase this risk. They should therefore be used with caution all the time and only under specialist supervision. Higher amputation rates have been reported with some SGLT-2 inhibitors and hence they should be used with caution in patients with peripheral vascular disease.

scholarly journals Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes

Diabetes Care ◽  
2016 ◽  
Vol 39 (4) ◽  
pp. 532-538 ◽  
Author(s):  
Anne L. Peters ◽  
Robert R. Henry ◽  
Payal Thakkar ◽  
Cindy Tong ◽  
Maria Alba
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Sodium Glucose Cotransporter
Sign in / Sign up

Export Citation Format

Share Document